Ja, es stimmt, es gibt einige Publikationen zu diesem Thema. So, wie ich die Literatur gelesen habe, geht es aber um Meningeom-Zellen in Zellkulturen. An Menschen wurde das höchstens experimentell durchgeführt, als Studie.
Hier ein paar Literaturstellen dazu, die ich gerade gefunden habe:
Eur J Cancer. 1991;27(4):416-9.
Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.Koper JW, Zwarthoff EC, Hagemeijer A, Braakman R, Avezaat CJ, Bergstrom M, Lamberts SW.
In this paper the results of investigations on the effect of interferon-alpha (IFN-alpha) on the growth of meningioma cells in culture is reported. A consecutive series of six meningiomas and one meningioma/neurofibroma derived from a patient with neurofibromatosis type 2 was investigated and it was found that the growth of all seven tumours in response to mitotic stimuli (fetal bovine serum or epidermal growth factor) is strongly inhibited by IFN-alpha. Maximal response varied between 100% and 70% inhibition of the incorporation of tritiated thymidine. In some cases an inhibitory response was obtained already at very low doses (less than or equal to 10 U of IFN-alpha per ml). These results indicate that further clinical investigation of the application of IFN-alpha to the treatment of meningioma is warranted.
--
Cancer Lett. 1996 Feb 27;100(1-2):99-105.
Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro.Zhang ZJ, Wang JL, Muhr C, Smits A.
Department of Neurology, University Hospital Uppsala, Sweden.
We have investigated the effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) on meningioma cells in two different culture systems, evaluated by the uptake of radiolabelled methionine. With both IFN-alpha and 5-FU an inhibitory effect on the uptake of radiolabelled methionine by the meningioma cells was demonstrated, and we found a synergistic inhibitory effect with a combination of IFN-alpha and 5-FU. To obtain a maximal inhibition of cell metabolism without causing cell toxicity, we were able to decrease the dose of 5-FU by simultaneously adding IFN-alpha. Our results suggest that a combined treatment of IFN-alpha and 5-FU may be a successful alternative for patients with inoperable meningiomas. A novel in vitro positron emission tomography technique was used for the study of metabolic changes in tumour cells caused by drug treatment, which is complementary to conventional cell culture techniques.
--
http://clincancerres.aacrjournals.org/cgi/content/full/7/8/2269Meningioma Treated with Interferon-, Evaluated with [11C]-L-Methionine Positron Emission TomographyCarin Muhr2, Olafur Gudjonsson, Anders Lilja, Magdalena Hartman, Zhi-Jia Zhang and Bengt Långström
Departments of Neurology [C. M., Z-J. Z.], Neurosurgery [O. G.], Radiology [A. L.], and Pathology [M. H.], and PET Center [B. L.], University Hospital, SE-75185 Uppsala, Sweden
Purpose: In meningioma patients with postoperative residual masses, recurrent or primarily inoperable tumors, positron emission tomography (PET) with [11C]-L-methionine was used to evaluate treatment efficacy of IFN-.
Experimental Design: Twelve patients were treated with IFN- at a dose of 1.5–5 million IU s.c. daily. PET, computed tomography, and/or magnetic resonance imaging were performed in all patients before and, at regular intervals, during IFN- treatment. The ratio of tumor hot-spot uptake to cerebellar uptake or to cortex uptake was calculated. This ratio estimates the relative methionine accumulation in the tumor and presumably the proliferative activity in the tumor.
Results: During IFN- treatment, PET demonstrated a mean relative percentage of reduction in the uptake ratio (MRelR) of 22.3% in the meningiomas. In nine patients who were considered responders, defined as patients with a positive MRelR, the MRelR was 30.4%. For the three nonresponders, defined as patients with a negative MRelR, the MRelR was -1.8%. Three patients were followed for a long time: two patients for 8 years and one patient for 4 years and 6 months; the two patients followed for 8 years are still on IFN. The volumes of these tumors were constant or showed a slight decrease. No correlation was found between histopathological diagnosis (PAD) WHO grading I–III of meningiomas and response to IFN- treatment.
Conclusions: PET was judged a useful method to predict which patients are suitable for long-term treatment with IFN- and also for dose finding. In five patients treated from 9 months to 8 years, IFN- seemed to be an effective oncostatic drug. The clinical usefulness of IFN-, taking adverse reactions into account, must be evaluated in a larger series of patients.
http://www.emedicine.com/NEURO/topic209.htmhttp://www.cancerhelp.org.uk/help/default.asp?page=4009
